
Two Experimental Eye Drugs Match the Standard Treatment for a Common Cause of Vision Loss
Kodiak Sciences said on Sept. 28 that both of the eye drugs it tested in the Phase 3 DAYBREAK trial met their primary endpoints in wet age-related macular degeneration. Each was non-inferior to…










